Brean Capital Remains Positive on Neuralstem Following NSI-566 Phase 2 Results
In a research note published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8 price target, after the company announced top-line results from its 15-patient Phase 2 trial with NSI-566 for ALS. Neuralstem shares are currently trading at $3.12, down $0.62 or 16.58 percent.
Aschoff noted, “Patients with better grip strength and other muscular parameters at entry responded better to NSI-566. We look forward to the initiation of a larger and controlled Phase 2 trial around mid-2015 that should enroll relatively healthy ALS patients based, in part, on grip strength. Beyond ALS, a Phase 1b trial with NSI-566 for cSCI is currently enrolling with data expected in 4Q15, and a Phase 1/2 trial with NSI-566 for ischemic stroke should roll over into Phase 2 in 2015. With small molecule drug NSI-189, we also look forward to Phase 2 data in schizophrenia with cognitive deficit in 1Q16, followed by Phase 2 data in MDD a year after.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 16.9% and a 65.4% success rate. Aschoff has a -3.1% average return when recommending CUR, and is ranked #76 out of 3511 analysts.